Evidence map›Paper›PMID 42620272›Full record

ArticleFrontiers in endocrinology2026

Aisha A Tepede, Maya Lee, James Welch, Adel Mandl, Craig Cochran, Ahmed Hamimi, Lee S Weinstein, William F Simonds, Ahmed M Gharib, Corina Millo and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04969926 (Natural History Study of Parathyroid Disorders), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04969926 recruitingnot on this map

Natural History Study of Parathyroid Disorders

TypeobservationalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran2021 to 2031Enrolled3,000ConditionsParathyroid Cancer, Primary Hyperparathyroidism, Pseudohypoparathyroidism, Inheritable Bone Diseases
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aisha A TepedeMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Maya LeeMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
James WelchMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Adel MandlMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Craig CochranMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Ahmed HamimiBiomedical and Metabolic Imaging Branch/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Lee S WeinsteinMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
William F SimondsMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Ahmed M GharibBiomedical and Metabolic Imaging Branch/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Corina MilloClinical Center PET Department (CC PET), National Institutes of Health, Bethesda, MD, United States.
Samira M SadowskiSurgical Oncology Program, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, United States.
Jenny E BlauMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.
Smita JhaMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD, United States.

Funding

Hyperparathyroidism-- Etiology, Diagnosis And TreatmentZIADK043006 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JHA, SMITA · 2011 to 2025
$8.9M
Intramural NIH HHS ZIA DK043006
6 · The paper itself

Abstract

Objective: The aim of this study was to evaluate the efficacy of 6-18F-fluoro-L-3,4-dihydroxyphenylalanine ( Design: This prospective MEN1 cohort study evaluated 16 genetically confirmed patients with MEN1. Inpatient subjects were imaged using CT, magnetic resonance imaging (MRI), Setting: The NIH Clinical Center was the setting for this study. Patients: Patients with germline Results: A total of 134 lesions were identified after review of CT, MRI, and Conclusion: Clinical Trial Registration: https://clinicalstudies.info.nih.gov/protocoldetails.aspx?id=000344-DK&&query=, identifier NCT04969926.

Indexed as

DihydroxyphenylalanineMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPositron Emission Tomography Computed TomographyAdultAgedCohort StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedOrganometallic CompoundsProspective StudiesRadiopharmaceuticalsDihydroxyphenylalaninefluorodopa F 18Organometallic CompoundsRadiopharmaceuticalsfunctional neuroendocrine tumorshepatic metastasesinsulinomaspancreatic neuroendocrine tumorsZollinger-Ellison syndrome

Identifiers

PMID42620272
PMCPMC13485575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.